Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 292 Shares

Key Points

• Solomon Moshkevich, an insider at Natera, sold 292 shares of the company's stock for a total value of $54,881.40, reducing his ownership by 0.25%.
• Natera reported a quarterly loss of ($0.74) earnings per share, missing analyst forecasts while posting revenues of $546.60 million, exceeding expectations.
• The company's stock has a current market cap of $25.81 billion and has recently traded around $188.02, with a 52-week range between $117.27 and $196.63.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 292 shares of Natera stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $187.95, for a total value of $54,881.40. Following the sale, the insider directly owned 117,267 shares of the company's stock, valued at $22,040,332.65. This trade represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $159.99, for a total value of $479,970.00.
• On Tuesday, September 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $166.62, for a total transaction of $499,860.00.
• On Thursday, August 14th, Solomon Moshkevich sold 875 shares of Natera stock. The shares were sold at an average price of $155.46, for a total value of $136,027.50.
• On Friday, August 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $132.89, for a total value of $398,670.00.
• On Monday, July 28th, Solomon Moshkevich sold 2,206 shares of Natera stock. The stock was sold at an average price of $139.81, for a total transaction of $308,420.86.

Natera Stock Performance

NTRA stock traded up $1.14 during midday trading on Wednesday, hitting $188.02. 1,333,479 shares of the stock were exchanged, compared to its average volume of 1,160,110. The stock has a market cap of $25.81 billion, a price-to-earnings ratio of -98.44 and a beta of 1.74. Natera, Inc. has a fifty-two week low of $117.27 and a fifty-two week high of $196.63. The stock's 50-day moving average price is $169.97 and its 200-day moving average price is $159.37.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business's revenue was up 32.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Hedge Funds Weigh In On Natera

Institutional investors have recently bought and sold shares of the stock. Bank of Jackson Hole Trust acquired a new stake in Natera in the 1st quarter valued at approximately $29,000. TCTC Holdings LLC raised its position in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after purchasing an additional 124 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock worth $33,000 after buying an additional 106 shares during the period. Hilltop National Bank bought a new stake in shares of Natera in the 2nd quarter worth about $33,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new stake in Natera during the 2nd quarter worth approximately $36,000. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on NTRA shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Natera in a research report on Wednesday, October 8th. Cowen reiterated a "buy" rating on shares of Natera in a research note on Friday, August 8th. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research report on Monday, July 28th. Morgan Stanley restated an "overweight" rating and issued a $195.00 target price on shares of Natera in a research note on Sunday, August 10th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $220.00 price objective (up from $210.00) on shares of Natera in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Natera has an average rating of "Moderate Buy" and an average target price of $196.81.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.